Glenmark Pharmaceuticals Launches Affordable GLIPIQ in India
Filing Summary
Glenmark Pharmaceuticals Ltd has launched GLIPIQ (semaglutide) in India, targeting the management of Type 2 Diabetes Mellitus. The treatment is priced starting at ₹325 per week, aiming to make GLP-1 therapy more accessible. GLIPIQ is available in vial and pre-filled pen formats, approved by the Central Drugs Standard Control Organization following a Phase III clinical study. The product is designed to offer flexible dosing and improve treatment adherence. Glenmark also introduces the ‘Sankalp’ patient support program to assist with therapy initiation and adherence.
Glenmark Pharmaceuticals Ltd has announced the launch of GLIPIQ (semaglutide) in India, aimed at managing Type 2 Diabetes Mellitus. The launch introduces a new pricing benchmark for GLP-1 therapy, with weekly treatment costs starting at ₹325. This initiative is intended to expand access to advanced diabetes treatment options for patients in India.
The financial aspect of this launch highlights the affordability of GLIPIQ, with treatment costs ranging from ₹325 to ₹440 per week. This pricing strategy is designed to lower the cost barrier for initiating GLP-1 therapy in India. The product is available in both vial and pre-filled pen formats, offering flexibility in treatment options and potentially enhancing patient adherence to therapy.
Operationally, GLIPIQ is available in vial-based formulations with dose-specific syringes, allowing for physician-guided dosing tailored to patient needs. This approach is particularly beneficial in the early stages of treatment. The vial format supports a cost-effective treatment pathway, while the pre-filled pen format offers convenience for long-term self-dosing. Both formats are available in strengths of 2 mg/1.5 mL, 4 mg/3 mL, and 8 mg/3 mL, providing structured treatment pathways that support continuity of care and improved adherence.
The market context for GLIPIQ includes its approval by the Central Drugs Standard Control Organization following a multicentre, randomised, comparative, active-controlled, open-label Phase III clinical study conducted in India. This study demonstrated favourable efficacy and safety outcomes in Indian patients with Type 2 diabetes. The launch of GLIPIQ is accompanied by the introduction of the ‘Sankalp’ patient support program, which is designed to assist with therapy initiation, improve comfort with injectable treatment, and enable long-term adherence.
The timeline for the launch of GLIPIQ in India was announced on March 21, 2026. The product is now available for patients, with Glenmark Pharmaceuticals Ltd overseeing its distribution and implementation across the Indian market.
About Glenmark Pharmaceuticals Ltd: Glenmark Pharmaceuticals is a global, research-led pharmaceutical company focused on innovation and accessibility. The company is committed to delivering high-quality and affordable medicines across a diversified portfolio, including branded, innovative, generics, and consumer health products. Glenmark operates 11 manufacturing facilities and six R&D centres, with a commercial presence in over 80 countries, focusing on respiratory, dermatology, and oncology sectors.